Literature DB >> 3056730

Heterogeneity in the molecular defect leading to the leukocyte adhesion deficiency.

M T Dimanche-Boitrel1, A Guyot, G De Saint-Basile, A Fischer, C Griscelli, B Lisowska-Grospierre.   

Abstract

Leukocyte adhesion deficiency (LAD) is a recessive autosomal disease characterized by life-threatening recurrent bacterial infections, by defective functions of leukocytes and by deficient membrane expression of leukocyte adhesion glycoproteins. These proteins, LFA-1, Mac-1 and p150,95, are alpha 1/beta 1 heterodimers composed of different alpha chains and of a common beta chain. Patients with the severe phenotype of the disease completely lack the three glycoproteins on cell surface. Previous studies showed a conserved synthesis of the LFA-1 alpha chain precursor in cytosol of patients' cells and an inconstant presence of the beta chain precursor. When present, precursors are in free form and not associated to alpha/beta complexes in the cells of patients with the severe phenotype. The availability of the beta chain cDNA probe allowed us to examine the beta chain gene expression in the lymphoblastoid cell lines of 4 patients. On the basis of the results obtained both at protein and RNA levels we can distinguish 3 types of mutations characterized by (a) barely detectable beta subunit messenger RNA and undetectable beta precursor, (b) decreased level of beta subunit mRNA and undetectable beta precursor and (c) normal beta subunit mRNA level and detectable beta precursor of normal size.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056730     DOI: 10.1002/eji.1830181016

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Gene therapy of primary immunodeficiencies.

Authors:  F Candotti; R M Blaese
Journal:  Springer Semin Immunopathol       Date:  1998

Review 2.  Leucocyte adhesion deficiency.

Authors:  M H el Habbal; S Strobel
Journal:  Arch Dis Child       Date:  1993-10       Impact factor: 3.791

3.  Effects of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) on the expression of LFA-1 in the moderate phenotype of leukocyte adhesion deficiency (LAD).

Authors:  M T Dimanche-Boitrel; F Le Deist; A Quillet; A Fischer; C Griscelli; B Lisowska-Grospierre
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

4.  A novel CD18 genomic deletion in a patient with severe leucocyte adhesion deficiency: a possible CD2/lymphocyte function-associated antigen-1 functional association in humans.

Authors:  L M Allende; M Hernández; A Corell; M A García-Pérez; P Varela; A Moreno; I Caragol; F García-Martín; J Guillén-Perales; T Olivé; T Español; A Arnaiz-Villena
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

5.  Anti-(human LFA-1) monoclonal antibodies bind P815 murine tumour cells.

Authors:  M J Palisson; A Altemeyer; I Moosbrugger; S Warter; G Hauptmann; P Bischoff
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Transfection of cells from patients with leukocyte adhesion deficiency with an integrin beta subunit (CD18) restores lymphocyte function-associated antigen-1 expression and function.

Authors:  M L Hibbs; A J Wardlaw; S A Stacker; D C Anderson; A Lee; T M Roberts; T A Springer
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Defects in adhesion molecules.

Authors:  K E Sullivan
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 10.817

8.  Distinct mutations in two patients with leukocyte adhesion deficiency and their functional correlates.

Authors:  A J Wardlaw; M L Hibbs; S A Stacker; T A Springer
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

Authors:  E Baixeras; B Huard; C Miossec; S Jitsukawa; M Martin; T Hercend; C Auffray; F Triebel; D Piatier-Tonneau
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.